ID
IDYA.O
—
NASDAQ
Biotechnology
Idya.O
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
-72,8 %
ROE
-11,1 %
Net margin
-52,0 %
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$35,59
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Ideaya Biosciences Inc operates in the biotechnology sector within the Health Care industry, though specific business activities and revenue generation mechanisms are not detailed in the available classification data.
Business. Ideaya Biosciences Inc operates in the biotechnology sector within the Health Care industry, though specific business activities and revenue generation mechanisms are not detailed in the available classification data.
Classification85 %
SectorHealth Care
Industry groupBiotechnology
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership→
JANUS HENDERSON GROUP PLC
largest disclosed fund holder
Profitability→
-11,1 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to IDYA.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Ideaya Biosciences Inc operates in the biotechnology sector within the Health Care industry, though specific business activities and revenue generation mechanisms are not detailed in the available classification data.
Classification85 %
SectorHealth Care
Industry groupBiotechnology
AI synthesis
GENERATED(a) Capital structure and liquidity: The company maintains a conservative balance sheet with total assets of $1.11 billion and total liabilities of $86.4 million, resulting in a debt-to-equity ratio of 0.0. Total equity stands at $1.02 billion, supported by cash and equivalents of $112.8 million. Despite the strong equity position, operating cash flow is negative at -$71.1 million, indicating ongoing cash burn typical of pre-profitability biotechnology firms. The current ratio is not explicitly provided, but the low debt load suggests minimal immediate solvency pressure.
(b) Profitability and returns: The company is not yet profitable, reporting a net income of -$113.7 million and an operating income of -$159.3 million against revenue of $218.7 million. Return on equity is -11.11% and return on assets is -10.25%, reflecting the significant investment phase characteristic of early-stage biotech companies. These metrics are consistent with firms prioritizing research and development over immediate earnings.
Key takeaways
- The company holds a strong cash position of $112.8 million with zero debt, providing a buffer against near-term liquidity issues.
- Significant operating losses of -$159.3 million and negative operating cash flow of -$71.1 million highlight the pre-profitability stage of the business.
- Low dilution risk suggests that recent share issuances or option exercises have not materially impacted shareholder equity in the short term.
- The absence of segment and geographic data limits the ability to assess revenue concentration risks or regional market dependencies.
- Classification confidence is low (0.20), indicating potential ambiguity in the company's specific industry positioning or business model clarity.
Bull / Bear case
analysis pipeline— missing data
In focus — financials by report
Valuation
Market price
$35,50
Market cap
—
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
$1.02B
Net cashⓘ
$112.8M
Current ratioⓘ
—
Debt / equityⓘ
—
ROAⓘ
-10.2%
ROEⓘ
-11.1%
Cash conversionⓘ
63.0%
CapEx / revenueⓘ
1.1%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
— missing data
Supply chain
— missing data
Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution16 analysts
Strong buy5
Buy10
Hold1
Sell0
Strong sell0
12-month price target$53,62 · Median $53,00
Low $37,00High $65,00
Operating income · consensus-430,2M USD
EPS surprise
+70,6 %
reported vs consensus · beat
Revenue surprise
+517,3 %
reported vs consensus · beat
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$37,00
Mean$53,62
Median$53,00
High$65,00
Spot$35,50
+51.0 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Op Margin-72,8 %Below median
Net Margin-52,0 %Below median
ROE-11,1 %Above median
Capex / Rev1,1 %Above median
D/E0,00Above median
Cash Conv0,63Below median
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 1 610 450 sh1 exercises · 13 grants13 insiders
- Chief Accounting Officer · Stock Option (Right to Buy) → Common StockDisposed 9 550 @ $12,86exercise · 2026-07-07
- Director · Stock Option (right to buy) → Common StockAcquired 20 000 @ $30,57grant · 2026-06-16
- Director · Stock Option (right to buy) → Common StockAcquired 20 000 @ $30,57grant · 2026-06-16
- Director · Stock Option (right to buy) → Common StockAcquired 20 000 @ $30,57grant · 2026-06-16
- Director · Stock Option (right to buy) → Common StockAcquired 20 000 @ $30,57grant · 2026-06-16
- Director · Stock Option (right to buy) → Common StockAcquired 20 000 @ $30,57grant · 2026-06-16
- Director · Stock Option (right to buy) → Common StockAcquired 20 000 @ $30,57grant · 2026-06-16
- Director, President and CEO · Stock Option (right to buy) → Common StockAcquired 600 000 @ $32,19grant · 2026-01-30
- SVP, General Counsel · Stock Option (right to buy) → Common StockAcquired 130 000 @ $32,19grant · 2026-01-30
- Chief Financial Officer · Stock Option (right to buy) → Common StockAcquired 170 000 @ $32,19grant · 2026-01-30
- Chief Scientific Officer · Stock Option (right to buy) → Common StockAcquired 190 000 @ $32,19grant · 2026-01-30
- Chief Medical Officer · Stock Option (right to buy) → Common StockAcquired 175 000 @ $32,19grant · 2026-01-30
- Chief Commercial Officer · Stock Option (right to buy) → Common StockAcquired 155 000 @ $32,19grant · 2026-01-30
- See Remarks · Stock Option (right to buy) → Common StockAcquired 80 000 @ $32,19grant · 2026-01-30
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
How metrics are computed
- Cash Conversion Ratiooperating_cash_flow / net_income
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Capex To Revenuecapital_expenditure / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
Source documents
- IDEAYA Biosciences, Inc. Market data — financials · 2026-07-30
- reconciler_enqueue (reconciler) on IDYA.O · 2026-07-30
Ownership & reference
Top holders
- Institutional Investor · as of 2026-03-310,12 %$242M
- Investment Managers · as of 2026-03-310,03 %$172M
- Institutional Investor · as of 2026-03-310,02 %$439M
- Investment Managers · as of 2026-03-310,01 %$29M
- Investment Managers · as of 2026-03-310,01 %$44M
- Investment Managers · as of 2026-03-310,01 %$55M
- Investment Managers · as of 2026-03-310,01 %$9M
- Investment Managers · as of 2024-06-300,01 %$239M
- Investment Managers · as of 2026-03-310,01 %$83M
- Investment Managers · as of 2026-03-310,01 %$0M
- Investment Managers · as of 2026-03-310,00 %$25M
- Investment Managers · as of 2026-03-310,00 %$126M
- Investment Managers · as of 2026-03-310,00 %$8M
- Investment Managers · as of 2026-03-310,00 %$62M
- Investment Managers · as of 2026-03-310,00 %$24M
- Investment Managers · as of 2026-03-310,00 %$5M
- Investment Managers · as of 2026-03-310,00 %$24M
- Investment Managers · as of 2025-12-310,00 %$174M
- Investment Managers · as of 2024-12-310,00 %$7M
- Investment Managers · as of 2026-03-310,00 %$8M
- Brokerage Firms · as of 2026-03-310,00 %$8M
- Institutional Investor · as of 2026-03-310,00 %$8M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$1M
- Funds · as of 2026-03-310,00 %$4M
- Institutional Investor · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Leadership
- Yujiro S. HataPresident, Chief Executive Officer, Director
Insider activity
Net buying1 buys · 1 sellsnet $1,3M3 insiders · last 365d
- Chief Accounting Officer · Common StockSold 9 550 @ $40,01$382K · 2026-07-07
- Chief Accounting Officer · Common StockOther 9 550 @ $12,86$123K · 2026-07-07
- Director · Common StockBought 50 000 @ $32,96$1,6M · 2026-03-02
- See Remarks · Common StockOther 1 253 @ $16,91$21K · 2025-11-28
- SVP, General Counsel · Common StockOther 1 041 @ $16,91$18K · 2025-11-28
Short positioning
9.6Mshares short-7.4% vs prior
8.61days to cover
65.8%short of daily vol
3fails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
IDYA.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Evidence & claims
From filings & derived data- Shareholders' equity (annual): USD 1.02BUnknown
- Current liabilities (annual): USD 58.81MUnknown
- R&D expense (annual): USD 314.7MUnknown
- Net income (annual): USD -113.7MUnknown
- Cash & equivalents (annual): USD 112.83MUnknown
- Operating income (annual): USD -159.31MUnknown
- Revenue (annual): USD 218.71MUnknown
- Operating cash flow (annual): USD -71.1MUnknown
- Current assets (annual): USD 666.73MUnknown
- EPS (basic) (annual): USD-PER-SHARES -1Unknown
- EPS (diluted) (annual): USD-PER-SHARES -1Unknown
- Capex (annual): USD 2.37MUnknown
- Total operating expenses (annual): USD 378.02MUnknown
- Total liabilities (annual): USD 86.39MUnknown
- Total assets (annual): USD 1.11BUnknown
- Shares outstanding (annual): 87.8MUnknown
- EPS (basic) (annual): USD-PER-SHARES -3Unknown
- Current liabilities (annual): USD 46.07MUnknown
- Capex (annual): USD 3.86MUnknown
- EPS (diluted) (annual): USD-PER-SHARES -3Unknown
- Current assets (annual): USD 689.71MUnknown
- R&D expense (annual): USD 294.67MUnknown
- Total assets (annual): USD 1.12BUnknown
- Total liabilities (annual): USD 64.94MUnknown
Showing 24 of 32 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-07-07INSIDERRuiz Briseno Andres sold 9.6k sh — Chief Accounting Officer ~$382k
2026-07-07INSIDERRuiz Briseno Andres transacted 9.6k sh — Chief Accounting Officer ~$123k
2026-07-07INSIDERRuiz Briseno Andres disposed of 9.6k sh Stock Option (Right to Buy) — Chief Accounting Officer
2026-06-16 00:00 UTCINSIDER6 insider transactions — 2026-06 6 derivative
2026-06-16 00:00 UTCINSIDER6 insider transactions — 2026-06 6 derivative
2026-06-16INSIDERMACKEY CATHERINE J acquired 20.0k sh Stock Option (right to buy) — Director
2026-06-16INSIDERHampton Malcolm Garret acquired 20.0k sh Stock Option (right to buy) — Director
2026-06-16INSIDERStein Jeffrey acquired 20.0k sh Stock Option (right to buy) — Director
2026-06-16INSIDERROSEN TERRY J acquired 20.0k sh Stock Option (right to buy) — Director
2026-06-16INSIDERMorrison Scott W acquired 20.0k sh Stock Option (right to buy) — Director
2026-06-16INSIDERYARNO WENDY L acquired 20.0k sh Stock Option (right to buy) — Director
2026-03-02 00:00 UTCINSIDER1 insider transaction — 2026-03 · net buy $1.6M
2026-03-02 00:00 UTCINSIDER1 insider transaction — 2026-03 · net buy $1.6M
2026-03-02INSIDERStein Jeffrey bought 50.0k sh — Director ~$1.65M
2026-01-30 00:00 UTCINSIDER7 insider transactions — 2026-01 7 derivative
2026-01-30 00:00 UTCINSIDER7 insider transactions — 2026-01 7 derivative
2026-01-30INSIDERDORMAN STUART acquired 155.0k sh Stock Option (right to buy) — Chief Commercial Officer
2026-01-30INSIDERHata Yujiro S acquired 600.0k sh Stock Option (right to buy) — Director, President and CEO
2026-01-30INSIDERSnyder Douglas B. acquired 130.0k sh Stock Option (right to buy) — SVP, General Counsel
2026-01-30INSIDERWHITE MICHAEL ANTHONY acquired 190.0k sh Stock Option (right to buy) — Chief Scientific Officer
2026-01-30INSIDERBleharski Joshua acquired 170.0k sh Stock Option (right to buy) — Chief Financial Officer
2026-01-30INSIDERBeaupre Darrin acquired 175.0k sh Stock Option (right to buy) — Chief Medical Officer
2026-01-30INSIDERRuiz Briseno Andres acquired 80.0k sh Stock Option (right to buy) — See Remarks
2025-11-28 00:00 UTCINSIDER2 insider transactions — 2025-11
2025-11-28 00:00 UTCINSIDER2 insider transactions — 2025-11
2025-11-28INSIDERRuiz Briseno Andres transacted 1.3k sh — See Remarks ~$21k
2025-11-28INSIDERSnyder Douglas B. transacted 1.0k sh — SVP, General Counsel ~$18k
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data
Premium coverage